What is Windgap Medical?
Windgap Medical, Inc. is an emerging, privately-held pharmaceutical company based in the Greater Boston area. The company's core innovation lies in its patented wet/dry drug delivery platforms, designed to enhance patient solutions. Its initial product targets the administration of epinephrine for anaphylaxis, with a broader development strategy encompassing additional products across various market segments. The company's trajectory suggests a focus on scaling its patented technology and expanding its therapeutic offerings.
How much funding has Windgap Medical raised?
Windgap Medical has raised a total of $49.3M across 10 funding rounds:
Private Equity
$1.5M
Multiple Rounds
$4.5M
Other Financing Round
$10K
Debt
$2.9M
Debt
$1M
Debt
$150K
Debt
$184K
Series B
$39M
Private Equity (2014): $1.5M, investors not publicly disclosed
Other Financing Round (2015): $61K led by Maine Angels
Debt (2015): $250K supported by Undisclosed
Series A (2015): $4.2M featuring Cherrystone Angel Group
Other Financing Round (2016): $10K backed by Maine Angels
Debt (2016): $2.9M, investors not publicly disclosed
Debt (2017): $1M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Debt (2021): $184K featuring PPP
Series B (2022): $39M backed by Cobro Ventures, Shepherd Kaplan, Taiwania Capital, and Molex Ventures
Key Investors in Windgap Medical
Cobro Ventures
Cobro Ventures is a private investment firm specializing in technology and biotechnology sectors, focusing on creating significant value during critical innovation phases. They support projects ranging from network performance management to targeted protein degradation and AI-guided therapy.
Shepherd Kaplan
Shepherd Kaplan Krochuck is an Investment Advisory firm that focuses on Wealth and Asset Management, established in 2001 and headquartered in Boston, Massachusetts.
Taiwania Capital
Taiwania Capital is a venture capital firm founded in 2017, focusing on investing in early-stage companies within enterprise software, autonomous systems, AI, IoT, robotics & drones, next-gen semiconductors, sensors, and cloud infrastructure.
What's next for Windgap Medical?
The recent major strategic investment signifies a critical growth phase for Windgap Medical, likely enabling the company to accelerate product development, expand its market reach, and potentially prepare for future commercialization milestones. This capital infusion, part of the company's $49.3M in total financing, will be instrumental in navigating the complex pharmaceutical landscape and bringing its innovative drug delivery systems to patients in need. The company's strategic positioning and ongoing development efforts indicate a strong potential for future advancements and market impact.
See full Windgap Medical company page
